Clinical Trial
doi: 10.1016/s0140-6736(94)90632-7.
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
Affiliations
- PMID: 7934495
- DOI: 10.1016/s0140-6736(94)90632-7
Item in Clipboard
Clinical Trial
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
Lancet.
.
Abstract
Our in-vitro, animal, and early clinical data suggest that tumour necrosis factor alpha (TNF alpha) is an important target for specific biological therapy in rheumatoid arthritis. We report the results of repeated treatment with a chimeric monoclonal antibody to TNF alpha (cA2) in patients having disease flares. 7 patients originally enrolled in an open-label trial completed two to four cycles, each of which was followed by a good clinical response, with median improvements in the swollen-joint count and C-reactive protein exceeding 80%. cA2 may be useful therapy in the control of acute disease flares in rheumatoid arthritis and treatment programmes including cA2 may be effective in the long-term management of this disease.
Similar articles
-
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.Lancet. 1994 Oct 22;344(8930):1105-10. doi: 10.1016/s0140-6736(94)90628-9. Lancet. 1994. PMID: 7934491 Clinical Trial.
-
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.Arthritis Rheum. 1998 Sep;41(9):1552-63. doi: 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W. Arthritis Rheum. 1998. PMID: 9751087 Clinical Trial.
-
Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2).Br J Rheumatol. 1997 May;36(5):589-93. doi: 10.1093/rheumatology/36.5.589. Br J Rheumatol. 1997. PMID: 9189062
-
Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.Immunol Rev. 1995 Apr;144:195-223. doi: 10.1111/j.1600-065x.1995.tb00070.x. Immunol Rev. 1995. PMID: 7590814 Review.
-
Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.BioDrugs. 2002;16(2):111-48. doi: 10.2165/00063030-200216020-00005. BioDrugs. 2002. PMID: 11985485 Review.
Cited by
-
Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.Jpn J Ophthalmol. 2012 Nov;56(6):536-43. doi: 10.1007/s10384-012-0182-z. Epub 2012 Oct 2. Jpn J Ophthalmol. 2012. PMID: 23053631
-
Joint-specific and systemic autoreactivity in the development of inflammatory arthritis.Arthritis Res. 2000;2(1):2-4. doi: 10.1186/ar64. Epub 1999 Dec 22. Arthritis Res. 2000. PMID: 11094413 Free PMC article. No abstract available.
-
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.Ann Rheum Dis. 2005 Jul;64(7):1003-8. doi: 10.1136/ard.2004.029124. Ann Rheum Dis. 2005. PMID: 15958758 Free PMC article.
-
The role of tumor necrosis factor-alpha in systemic lupus erythematosus.Arthritis Res Ther. 2008;10(1):202. doi: 10.1186/ar2341. Epub 2008 Jan 23. Arthritis Res Ther. 2008. PMID: 18226185 Free PMC article. Review.
-
Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.Cancer Immunol Immunother. 1995 Jun;40(6):367-75. doi: 10.1007/BF01525387. Cancer Immunol Immunother. 1995. PMID: 7627993 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
